INSPECS Group plc (AIM:SPEC)
London
· Delayed Price · Currency is GBP · Price in GBX 40.00
+1.00 (2.56%)
Apr 17, 2025, 12:35 PM GMT+1
INSPECS Group Revenue
In the year 2024, INSPECS Group had annual revenue of 198.26M GBP, down -2.48%. INSPECS Group had revenue of 95.21M in the half year ending December 31, 2024, a decrease of -0.97%.
Revenue
198.26M
Revenue Growth
-2.48%
P/S Ratio
0.21
Revenue / Employee
119.87K
Employees
1,673
Market Cap
40.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 198.26M | -5.03M | -2.48% |
| Dec 31, 2023 | 203.29M | 2.34M | 1.16% |
| Dec 31, 2022 | 200.96M | -45.51M | -18.47% |
| Dec 31, 2021 | 246.47M | 199.06M | 419.82% |
| Dec 31, 2020 | 47.42M | -13.83M | -22.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.19B |
| GSK plc | 31.38B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Oxford Nanopore Technologies | 183.19M |